Madison Asset Management LLC Has $15.61 Million Position in AbbVie Inc. $ABBV

Madison Asset Management LLC cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 4.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 67,401 shares of the company’s stock after selling 2,791 shares during the period. Madison Asset Management LLC’s holdings in AbbVie were worth $15,606,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ABBV. Vanguard Group Inc. boosted its position in AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of AbbVie by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after purchasing an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of AbbVie by 6.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after buying an additional 1,517,222 shares during the last quarter. Norges Bank bought a new position in shares of AbbVie in the second quarter valued at $4,288,200,000. Finally, Raymond James Financial Inc. increased its holdings in AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after buying an additional 2,753,312 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive: AbbVie’s real‑world PHASES migraine study could expand uptake for ubrogepant (an oral migraine treatment), improving its competitive positioning in migraine care and incremental revenue potential. AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
• Positive Sentiment: Positive: AbbVie updated its Phase 2 elezanumab study in acute cervical spinal cord injury — any favorable signals in neuroscience would bolster the pipeline and longer‑term growth optionality beyond immunology and aesthetics. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch
• Neutral Sentiment: Neutral: Analyst coverage is shifting — some upgrades/notes frame AbbVie as a stronger value/growth combination given Rinvoq and Skyrizi momentum, which supports the longer‑term revenue thesis but may be priced in. How Recent Analyst Shifts Are Reframing AbbVie (ABBV) And Its Valuation Story
• Neutral Sentiment: Neutral: Research/commentary expects 2026 top‑line growth from Rinvoq and Skyrizi (offsetting Humira erosion); these projections support consensus revenue targets but leave sensitivity to execution and pricing. Here’s What Will Drive AbbVie’s Top-line Growth in 2026
• Neutral Sentiment: Neutral: Coverage highlighting AbbVie as a value/attractive income stock (Zacks, Seeking Alpha mentions) can support demand from income‑oriented investors even as valuation debates continue. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Negative Sentiment: Negative: The big near‑term headwind is CMS selecting Botox for price negotiation under the Inflation Reduction Act; AbbVie filed suit against HHS challenging the move. If price controls are upheld, Botox revenue and pricing could be materially affected; the lawsuit increases regulatory uncertainty and likely pressured shares. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Negative: Reports that AbbVie is reshaping U.S. operations with Medicaid concessions and broader pricing/alignment moves (including commentary about large domestic manufacturing deals) suggest margin and access tradeoffs; these actions can depress near‑term profitability even if they support market access. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

Wall Street Analyst Weigh In

ABBV has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Evercore dropped their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. UBS Group decreased their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Finally, Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Trading Down 0.8%

Shares of NYSE ABBV opened at $220.74 on Thursday. The firm has a market cap of $390.12 billion, a P/E ratio of 93.53, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. The business’s 50 day moving average is $223.47 and its 200-day moving average is $220.29. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the firm posted $2.16 EPS. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.